{
    "pmcid": "9230756",
    "qa_pairs": {
        "How can nanobodies be administered to treat respiratory diseases effectively?": [
            "Nanobodies can be administered via inhalation for direct delivery to the lungs.",
            "Nanobodies are administered intravenously for systemic distribution.",
            "Nanobodies are delivered through oral tablets for ease of use.",
            "Nanobodies require subcutaneous injections for effective delivery."
        ],
        "What is a challenge mentioned in the clinical development of nanobodies?": [
            "Regulatory approval, as only one nanobody has been FDA approved for a non-viral indication.",
            "Lack of effective delivery methods for nanobodies in respiratory diseases.",
            "Inability to produce nanobodies at a scale required for clinical use.",
            "High immunogenicity of nanobodies in human patients."
        ],
        "What is a key target for nanobodies in combating SARS-CoV-2?": [
            "The spike protein, particularly the receptor-binding domain (RBD).",
            "The nucleocapsid protein of SARS-CoV-2.",
            "The membrane protein of SARS-CoV-2.",
            "The envelope protein of SARS-CoV-2."
        ],
        "What is a strategy mentioned for extending the half-life of nanobodies?": [
            "Fusing nanobodies with human serum albumin or IgG1 Fc fragments.",
            "Increasing the molecular weight of nanobodies through chemical modification.",
            "Administering nanobodies with a booster dose to prolong their presence.",
            "Encapsulating nanobodies in lipid nanoparticles for sustained release."
        ],
        "What is one advantage of nanobodies over conventional antibodies in terms of production?": [
            "Nanobodies can be easily produced in bacterial systems, reducing production costs.",
            "Nanobodies require complex mammalian cell culture systems for production.",
            "Nanobodies are produced using yeast systems, which are more expensive than bacterial systems.",
            "Nanobodies need to be synthesized chemically, increasing production costs."
        ]
    }
}